Serum‐autoantibodies for discovery of prostate cancer specific biomarkers

Massoner, Petra; Lueking, Angelika; Goehler, Heike; Höpfner, Annabel; Kowald, Axel; Kugler, Karl G.; Amersdorfer, Peter; Horninger, Wolfgang; Bartsch, Georg; Schulz‐Knappe, Peter; Klocker, Helmut

doi:10.1002/pros.21444

Cited by 36 publications

(34 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies against a number of tumour-associated antigens (TAAs) have been found in the serum of prostate cancer patients (Massoner et al, 2012;Cho-Chung, 2006;Ummanni et al, 2015). Due to their presence following any perturbation in the cellular microenvironment (e.g.…”

Section: Other Potential Approaches To Improve Pca Diagnosismentioning

confidence: 99%

Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools

Sharma

Zapatero-Rodríguez

O’Kennedy

2017

Biotechnology Advances

View full text Add to dashboard Cite

Section: Other Potential Approaches To Improve Pca Diagnosismentioning

confidence: 99%

Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools

Sharma

Zapatero-Rodríguez

O’Kennedy

2017

Biotechnology Advances

View full text Add to dashboard Cite

“…This is due to, for example, overexpression, as in the case of AMACR [135]. Recent developments have targeted this autoimmune response in the development of multiplex arrays to detect autoimmune signatures that outperform PSA in detecting PCa with high specificity and sensitivity [148], and discriminate between PCa and BPH [149]. …”

Section: Current and Emerging Biomarkersmentioning

confidence: 99%

Current Status of Biomarkers for Prostate Cancer

Velonas

Woo

Remedios

et al. 2013

IJMS

197

152

View full text Add to dashboard Cite

Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rates of false positive results and is not prognostic. Here we review the current status of molecular biomarkers that promise to be prognostic and that might inform individual patient management. It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles.

show abstract

“…Nonetheless, measurement of a single autoantibody may lack sufficient sensitivity required for cancer screening and diagnosis (13). In order to overcome this problem, subsequent studies have provided better sensitivity in the diagnosis of cancer by screening for multiple autoantibodies toward a panel of TAAs (10,14,15,16,17,18,19,20,21). However, most of these reports had limitations, such as small study size and single-cohort study design.…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma

Peng

Chen

et al. 2014

American Journal of Gastroenterology

104

114

View full text Add to dashboard Cite

OBJECTIVES:Esophageal squamous cell carcinoma (ESCC) is one of the most frequent causes of cancer death worldwide and effective diagnosis is needed. We assessed the diagnostic potential of an autoantibody panel that may benefit early diagnosis.METHODS:We analyzed data for patients with ESCC and normal controls in a test cohort and a validation cohort. Autoantibody levels were measured against a panel of six tumor-associated antigens (p53, NY-ESO-1, matrix metalloproteinase-7 (MMP-7), heat shock protein 70 (Hsp70), peroxiredoxin VI (Prx VI), and BMI1 polycomb ring finger oncogene (Bmi-1)) by enzyme-linked immunosorbent assay.RESULTS:We assessed serum autoantibodies in 513 participants: 388 with ESCC and 125 normal controls. The validation cohort comprised 371 participants: 237 with ESCC, and 134 normal controls. Autoantibodies to at least 1 of 6 antigens demonstrated a sensitivity/specificity of 57% (95% confidence interval (CI): 52–62%)/95% (95% CI: 89–98%) and 51% (95% CI: 45–57%)/96% (95% CI: 91–99%) in the test and validation cohorts, respectively. Measurement of the autoantibody panel could differentiate early-stage ESCC patients from normal controls (sensitivity 45% (95% CI: 32–59%) and specificity 95% (95% CI: 89–98%) in the test cohort; 46% (95% CI: 35–58%) and 96% (95% CI: 91–99%) in the validation cohort). In either cohort, no significant differences were seen when patients were subdivided by age, gender, smoking status, size of tumor, site of tumor, depth of tumor invasion, histological grade, lymph node status, TNM stage, or early-stage and late-stage groups.CONCLUSIONS:Measurement of an autoantibody response to multiple tumor-associated antigens in an optimized panel assay, to help discriminate early-stage ESCC patients from normal controls, may aid in early detection of ESCC.

show abstract

Serum‐autoantibodies for discovery of prostate cancer specific biomarkers

Cited by 36 publications

References 46 publications

Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools

Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools

Current Status of Biomarkers for Prostate Cancer

Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About